CTLA4 and neoplasm: Furthermore, we investigated 22 key immune checkpoint modulators in HCC, since these co-stimulatory or inhibitory modulators, especially CTLA-4, PD-1, or PD-L1, may sustain or restrict the anti-tumoral potency of tumor-associated T cells (48).